Additionally, ribavirin, an anti-viral guanosine analogue, identified as a direct eIF4E inhibitor, was shown to enhance the therapeutic effects of cytarabine in a clinical trial involving AML patients [41]. This evidence concerns the gene EIF4E and acute myeloid leukemia.